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SUMMARY
The gene for the coagulation protein factor Vil contains several common
restriction fragment length polymorphisms which can be used to analyse the
pattern ofinheritance offactor VIIIalleles within families. This can beexploited to
identify carriers ofhaemophilia, an X-linked inherited disorder characterised by
deficiency offactor VIIL. In this study thepolymerase chain reaction was used to
analyse a polymorphism recognisd by the restriction enzyme Bcll, located at
intron 18 ofthefactor VIIIgene. The restrictionfragmentpatterns generated were
used to track the inheritance ofmutatedfactor VIIIalleles withinfamilies allowing
haemophilia carrier status to be determined in individuals at risk.
INTRODUCTION
Haemophilia is an X-linked inherited disorder which affects one male in 10,000.
The condition is characterised by abnormal bleeding due to the deficiency of
factor VIII, a protein necessary for normal coagulation. The deficiency is caused
by heritable mutations within the factor Vill gene. Male off-spring of female
carriers have a 50% chance ofmanifesting the condition. Female off-spring have
a 50% chance of being carriers. Determination of haemophilia carrier status
facilitates counselling of individuals at risk of having an affected child, allowing
them to make informed choices regarding parenthood.
Initial attempts to identify carriers were based on measurements of the factor
Vill coagulant activity in the plasma.' This approach proved unreliable due
to the physiological variability in factor Vill levels and the random nature of
X chromosome inactivaction in females.2 The advent of recombinant DNA tech-
nology has permitted unequivocal identification of carriers in about two-thirds of
cases using restriction fragment length polymorphisms (RFLPs).3 These are
naturally occurring variations in DNA sequence which alter the pattern of
fragments produced when DNA corresponding to a particular gene istreated with
a restriction endonuclease. The variations can be exploited to distinguish not only
between genes carried by different individuals, but also between homologous
pairs of genes (alleles) within individuals. Three common RFLPs occur in the
factor VIII gene located at introns 18, 22, and 26. They are recognised by the
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restriction enzymes, Bcll,4 Xbal5 and Bgl1.6 By analysing the restriction frag-
ment pattern of the factor VIII gene in DNA from a haemophilic patient using
these enzymes, it is possible to identify the RFLP pattern associated with the
X chromosome carrying the mutated gene. By comparing the pattern with that
generated by the mother and sisters ofthe haemophilic, it is possible to trace the
inheritance pattern of the mutated gene within the family and so to establish
carrier members.
Restriction fragment length polymorphismscan beanalysed using thepolymerase
chain reaction.7 The technique allows an individual gene, contained within a
complex mixture ofgenes such as chromosomal DNA, to be copied exclusively in
a simple enzyme catalysed reaction until its DNA becomes the dominant species
in the reaction mixture and enough is obtained to allow detailed analysis of that
gene. Individual genes can be amplified about one million fold, and up to 1pg of
specific DNA can be obtained.
This paper describes how the polymerase chain reaction was used to amplify the
part of the factor Vill gene containing a RFLP recognised by the enzyme Bcll,
and how analysis of the restriction fragment pattern of the amplified DNA with
Bcll was used to identify carriers of haemophilia.
MATERIALS AND METHODS
Purification of chromosomal DNA: Human chromosomal DNA was prepared
from 15ml of anti-coagulated blood.8 A typical yield of 200pg of purified DNA
was obtained.
Synthesis of oligonucleotide primers: Primers used to amplify the factor Vill
intron 18 RFLP were synthesized by British Biotechnology Ltd. Their sequences
have been described previously.9
Polymerase chain reaction (PCR): A DNA sequence corresponding to part of
intron 18 of the factor VIII gene was amplified selectively from human chromo-
somal DNA. A reaction mixture (100I) was prepared which contained: lpg
chromosomal DNA, 200iM each of dATP, dTTP, dGTP and dCTP (Pharmacia
Ltd), 50 pmoles of each primer, 5 units of Taq DNA polymerase (Perkin Elmer
Ltd) and PCR reaction buffer (1OmM-Tris, pH 8-3, 5OmM-KCI, 1 *5mM-Mgcl2
and 0 01 % gelatin).
The chain reaction was carried out using an automated DNA thermal cycler
(Perkin Elmer Ltd). Samples were initially denatured at 94°C for 4 min, followed
by 25 cycles of 94°C for 1 min, 50°C for 2 min and 720C for 2 min. After the
reaction was completed, samples were stored at 4°C pending analysis.
Digestion of amplified DNA by Bcll restriction enzyme: Amplified DNA was
precipitated from the PCR reaction mixture with ethanol and redissolved in sterile
water. It was digested with Bcll according to the manufacturer's instructions
(Promega Ltd).
Analysis ofpolymerase chain reaction products: DNA, amplified by PCR and
digested by Bcll, was analysed by electrophoresis on 7-5% polyacrylamide
gels.8 The gels were then stained with ethidium bromide and visualised under
UV light.
© The Ulster Medical Society, 1993.
22Haemophilia carrier identification
Patients: A total of 139 haemophilia A patients from 89 families in Northern
Ireland are registered with the Regional Haemophilia Centre, based in the depart-
ment of haematology, Royal Victoria Hospital, Belfast. Only families of severely
affected patients (59/139) are investigated routinely. Of ten families studied,
haemophilia carrier status was successfully assigned in nine using the intron 18
RFLP in combination with RFLPs in introns 22 and 26 of the factor Vill gene and
the extragenic X chromosome probe DX13.10 The details of two families are
described showing the detection of one carrier and two non-carriers.
RESULTS
Analysisof thepolymerase chain reaction products by polyacrylamidegel electro-
phoresis revealed a single species ofamplified DNA represented by a band whose
length was calculated to be 142 base pairs by comparison with DNA marker
molecules of known length. This value is in agreement with that predicted from
the relative positions of the primers on the factor VIII gene.9
Analysis of amplified DNA which had been treated with Bcll revealed several
different banding patterns depending on theDNAsample used in the PCR reaction
(Fig 1). In some cases, the banding pattern was unchanged from that observed for
undigested samples and a single band of 142 base pairs was seen. This corres-
ponded to samples in which the factor Vill intron 18 DNA sequence was such
that no recognition site for Bcll was present. In other cases, the 142 base pair
band was lost and was replaced by two smaller bands of 99 and 43 base pairs.
This corresponded to samples in which the DNA sequence was such that a Bcll
site was present resulting in the fragmenfation of the 142 base pair band into two
smaller bands on treatment with Bcll. In some cases, treatment of amplified
DNA with Bcll produced a 142 base pair band as well as bands of 99 and 43
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Fig 1. A 142 bp segment of intron 18 of the factor Vil gene containing a polymorphic BcIlsite was
amplified by the polymerase chain reaction. Digestion of the reaction product with the enzyme Bcll
produced sub-fragments of 99 and 43 bp.
© The Ulster Medical Society, 1993.
23The Ulster Medical Journal
base pairs. This pattern represented heterozygous females with a Bcll site
present on one allele generating the 99/43 base pair bands and the other allele
lacking a Bcll site resulting in the 142 base pair band. It should be noted that
the shortness of the 43 base pair band resulted in a reduced amount of ethidium
bromide stain being bound causing it to be only faintly visible on gel photographs.
The 99 base pair band is however clearly visible and indicates cleavage of the
intron 18 Bcll site.
TABLE
Intron 18 RFLP analysis in two families with haemophilia
Intron 18
Family Individual Genotype Bcll site Phenotype
HI 11 -/ (99, 43) + unaffected
12 142 / (99, 43) - /+ carrier
111 -/ (99, 43) + haemophilic
112 142/- - unaffected
113 142 / (99, 43) -/+ non-carrier
H2 11 -/ (99, 43) + unaffected
12 142 / (99, 43) -/+ carrier
Ill -/ (99, 43) + haemophilic
112 142/ (99, 43) -/+ non-carrier
113 (99, 43) / (99, 43) +/+ carrier
Carriers of haemophilia were identified in several families by analysing the intron
18 RFLP in individuals. The strategy adopted was to identify the banding pattern
associated with the X chromosome carried by a haemophilic and to use it to trace
the pattern of inheritance of the affected X chromosome within the family. The
results of typing for carrier status in families H1 and H2 are shown in the Table.
The family tree and intron 18 PCR results for family H1 are shown in Fig 2.
Interpretation ofthese PCR results is as follows: The father (11) demonstrates two
bands of 99 and 43 base pairs indicating that a Bcll site is present on his single
X chromosome at intron 18 of his factor VIII gene. The mother (12) shows three
bands of 142, 99 and 43 base pairs. This indicates that she is heterozygous with
a Bcll site present on one X chromosome (represented by the 99/43 base pair
bands) but absent from the other (represented by the 142 base pair band). The
son (111) who suffers from haemophilia has the 99/43 base pair combination of
bands indicating that of his mother's two X chromosomes, he has inherited the
one which contains a Bcll site and that this chromosome is associated with
haemophilia in this family. In contrast, the unaffected brother (112) has inherited
the other maternal X chromosome indicated by the presence of a single band at
142 base pairs. The daughter's results (113) indicate that she is heterozygous for
the Bcll site with all three bands present. The 99/43 base pair bands must be of
paternal origin implying that, of the two maternal alleles, she has inherited the
one represented by the 142 base pair band and, since it has been establised that
this allele is not associated with haemophilia in this family, it can be said that she
is not a carrier of haemophilia.
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Fig 2. Family H1. (A) Polyacrylamide gel showing Bcll digests ofamplified DNA. (B) Family tree
showing intron 18 genotypes and carrier status of individuals. The 43 base pair bands are only faintly
visible and have been marked X.
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Fig 3 shows results for family H2. As in the previous family, the father (11) shows
the 99/43 base pair combination and the mother (12) is heterozygous demon-
strating all three possible bands. The haemophilic son (111) has the 99/43 base
pair combination indicating the maternal allele associated with haemophilia. The
patterns obtained for the two daughters are different. One (112) is heterozygous;
the99/43 basepair combinationareofpaternal origin, implying thatthematernal
allele represented by the 142 base pair bands has been inherited, and since this
allele is not associated with haemophilia, she can be classified as a non-carrier.
The other daughter shows only the 99/43 base pair combination of bands indic-
ating that both alleles possess a Bcll site, one of which is paternal and the other
maternal. Since the maternal allele in this case is associated with haemophilia,
she must be classified as a carrier.
DISCUSSION
The use of restriction fragment length polymorphisms to identify carriers of
haemophilia representsanimprovement onprevious methods basedon measure -
ments of factor Vill plasma clotting activity.3 Because the restriction fragment
length polymorphism used is intragenic, it was possible to track the inheritance
pattern ofthe X chromosome carrying the mutated gene within the pedigree with
complete certainty. The results of carrier testing by this method should therefore
be considered unequivocal. This contrasts with methods based on phenotypic
data which give only a probability ofcarriership and have a finite error rate.1
The most important limitation of this method is the necessity that the alleles have
different DNA sequences at the RFLP, which generate different banding patterns
allowing them to be distinguished from each other. In a proportion of cases both
allelesofacarrier femalewill have thesame sequence, making theXchromosome
carrying the mutation indistinguishable from its homologous partner. For any
RFLP, the maximum percentage of individuals who will be heterozygous is 50%.
For the factor Vill intron 18 RFLP, the proportion of females who are hetero-
zygous is reported to be 42%.4 This figure represents the proportion of cases
in which this RFLP will permit assignment of carrier status. This value can be
increased by analysis of other factor Vill RFLPs in tandem with the intron 18
RFLP. In this way, the proportion of individuals who are heterozygous can be
increased to about 65%. The use of two other RFLPs which lie outside the factor
VIII gene increases the percentage to about 90% although the possibility of
recombination during gametogenesis resulting inthe separation ofthe RFLP from
the gene means thatthe result cannot be considered to be unequivocal.3 Recently
a multi-allele system for identifying carriers has been developed. It is based on
repetitive sequences of variable length in the factor VIII gene, and is reported to
be informative for 95% of females."
The method described in this paper allows haemophilia carrier status to be deter-
mined in about 40% of cases. It can be carried out rapidly (usually within 24h)
and without great technical difficulty on a semi-routine basis. The technique is
potentially applicable to any inherited disorder for which the aberrant gene is
known and for which RFLPs have been characterised. The approach represents
an important interface between clinical medicine and the rapidly expanding field
of molecular biology.
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Fig 3. Family H12. (A) Polyacrylamide gel showing Bcll digestsofamplified DNA. (B) Family tree
showing intron 18 genotypes and carrier status of individuals.
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